The Food and Drug Administration (FDA) has approved a quadrivalent formulation of Flublok influenza vaccine (Protein Sciences). Flublok Quadrivalent contains the three strains found in trivalent Flublok plus an additional B strain.
Compared to other quadrivalent influenza vaccines, Flublok Quadrivalent contains three times more active ingredient, making it the first high antigen quadrivalent vaccine approved by the FDA.
In a clinical study of 9,000 adults 50 years of age and older, people who received Flublok Quadrivalent were over 40% less likely to get cell-culture confirmed influenza than those that received a leading egg-produced quadrivalent flu vaccine.
Flublock Quadrivalent is indicated for active immunization against disease caused by influenza A virus subtypes and influenza B virus contained in the vaccine. It is approved for patients 18 years of age and older.
Just like the trivalent formulation, Flublok Quadrivalent is a recombinant protein-based vaccine that contains no egg proteins, antibiotics, or preservatives.
For more information visit ProteinSciences.com.